Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary Objective * To evaluate if the end of induction MRD-negative rate is higher in patients with T-ALL treated with dasatinib compared to similar patients treated with 4-drug induction on AALL1231. * To evaluate if the end of induction MRD-negative rate is higher in patients with ETP or near-ETP ALL treated with venetoclax compared to similar patients treated with 4-drug induction on AALL1231. Secondary Objectives * To assess the event free and overall survival of patients treated with this therapy. * To compare grade 4 toxicities, event-free survival (EFS) and overall survival (OS) of patients treated with this therapy in induction and reinduction to toxicities of similar patients treated on TOT17.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 do 18,99 roku życia
- •Rozpoznana białaczka limfoblastyczna typu T, chłoniak limfoblastyczny lub mieszana ostra białaczka
- •Brak wcześniejszego leczenia chemioterapią (poza terapią dozwoloną w badaniu INITIALL)
- •Rozpoczęto maksymalnie 3 dni chemioterapii w badaniu INITIALL
- •Prawidłowe parametry wątroby (bilirubina bezpośrednia i aminotransferaza)
- •Prawidłowa funkcja nerek (wykazana za pomocą specjalnych testów)
✗ Disqualifies
- •Brak zgody rodzica/opiekuna na udział w badaniu
- •Problemy z przewodem pokarmowym uniemożliwiające przyjmowanie leków doustnych
- •Zakażenie HIV lub hepatitis B/C
- •Ciąża lub karmienie piersią
- •Przyjmowanie pewnych leków (np. ryfampicyna, karbamazepina) w ciągu 7 dni przed rozpoczęciem badania
- •Konsumpcja grapefruit'u lub produktów z grapefruit'u
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Rady Children's Hospital
San Diego, United States
Novant Health Presbyterian Hemby Children's Hospital
Charlotte, United States
Saint Francis Children's Hospital
Tulsa, United States
St. Jude Children's Research Hospital
Memphis, United States
Trial contact
Seth E. Karol, MD, MSCI
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.